Good MorningEquities slipped again on Wednesday with the FOMC’s Beige Book in the market’s focus. The Beige Book revealed improving conditions but also a growing uncertainty spurred by the resurgence of COVID-19 as well as mounting inflation. The key takeaway from the report is that the FOMC is still on track to begin tapering sometime this year.
The market may get another clue as to when that will happen on Friday with the release of the PPI data. The consensus is for producer price increases to moderate from a 1.0% monthly gain posted in August to a slower 0.6% gain in September. Even so, producer level inflation is rising quickly and will lead to higher consumer prices down the road. If the PPI comes in hotter than expected the FOMC could begin the taper as soon as the September meeting in two weeks’ time.
Featured: 69% a year return. One type of stock. Really? (Investing Daily) 
|
Stocks | | | For some traditional investors, it may be easy to dismiss the retail trading community on Reddit. This band of retail investors is seen as a catalyst for the rise in “meme stocks” such as GameStop and AMC Entertainment. MarketBeat tracks the number of mentions a company receives on Reddit and lets investors identify companies that may be poised for future growth. Read the Full Story |
|
From Our PartnersThrough Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock…
And bought this instead!
He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to… | | | | See full story here… |
|
Markets | | | That’s the type of reliability that investors can bank on for the long run, and some of these stocks also offer upside in terms of price appreciation. If you are interested in generating passive income with stocks, here are 3 dividend aristocrat stocks to buy now Read the Full Story |
|
Tech | | | Stocks are closing lower on Wall Street Wednesday following a Federal Reserve report that shows U.S. economic activity slowed this summer amid rising worries over resurgent coronavirus cases and mounting supply chain problems and labor shortages Read the Full Story |
|
From Our PartnersThat's the power of using a simple trading strategy that 99% of investors miss. Free book reveals the step-by-step plan. | | So get it here now... |
|
Tech | | | An avalanche of changes launched by China’s ruling Communist Party has jolted everyone from tech billionaires to school kids. Behind them: President Xi Jinping’s vision of making a more powerful, prosperous country by reviving revolutionary ideals, with more economic equality and tighter party contr... Read the Full Story |
|
Tech | | | Technology companies that led the charge into remote work as the pandemic unfurled are confronting a new challenge: how, when and even whether they should bring long-isolated employees back to offices that have been designed for teamwork.
“I thought this period of remote work would b... Read the Full Story |
|
From Our PartnersMan who called the 2020 crash 45 days early shares "alarming" signals from the stock market today and what it means for August... | | | | Learn More Here! |
|
Markets | | | If you happened to hold Kirkland’s (NASDAQ:KIRK) stock throughout all of last year, you enjoyed a mind-blowing 1,342% return. The home décor retailer was among the top 10 U.S. stock performers in 2020 Read the Full Story |
|
Politics | | | Stocks fell in afternoon trading Wednesday as investors wait for more guidance from the Federal Reserve and monitor the direction of the coronavirus pandemic.
The S&P 500 index was down 0.2% as of 12:23 p.m. Eastern. The Dow Jones Industrial Average fell, 70 points or 0.2%, to 35,... Read the Full Story |
|
Markets | | |
Index funds are a curious thing.
On the one hand, plenty of long-term investors swear by them as a way of automating retirement investing and creating an allocated portfolio.
On the other hand, some investors correctly point out that an over-reliance on index funds can limit other in... Read the Full Story |
|
Politics | | | The U.N.-backed program to get vaccines to the neediest people in the world has again scaled back its target to ship doses this year, projecting about 1.4 billion doses will available through by the end of the year Read the Full Story |
|
Markets | | | Baby monitor and products make Owlet (NYSE: OWLT) stock has been pummeled so far in 2021. Most recently shares collapsed over (-20%) to all-time lows on new that the SEC has allowed warrant holders to exercise their options. Read the Full Story |
|
The Early Bird Stock Of The Day Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. | | View Today's Stock Pick |
|
